Matched-paired analysis of patients treated for invasive
mucormycosis: standard treatment versus posaconazole new
formulations (MoveOn)

J 2019

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

SALMANTON-GARCIA, Jon; Danila SEIDEL; Philipp KOEHLER; Sibylle C. MELLINGHOFF; Raoul HERBRECHT et al.

Základní údaje

Originální název

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Autoři

Vydání

Journal of Antimicrobial Chemotherapy, OXFORD, Oxford University Press, 2019, 0305-7453

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30303 Infectious Diseases

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.439

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00112622

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

LIPOSOMAL AMPHOTERICIN-B; MYCOSES STUDY-GROUP; TRANSPLANT RECIPIENTS; EUROPEAN-ORGANIZATION; TABLET FORMULATION; FUNGAL-INFECTIONS; ORAL TABLET; PHARMACOKINETICS; THERAPY; SAFETY

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 1. 2020 12:42, Mgr. Tereza Miškechová

Anotace

V originále

Background: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods: We performed a case-matched analysis with proven or probable IM patients from the FungiScope (R) Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n=4/5) of patients receiving 1st-POSnew, for 27.8% (n=5/18) receiving 1st-AMB+POSnew and for 50.0% (n=11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n=1/5) in 1st-POSnew versus 53.3% (n=8/15) in 1st-AMB; 33.3% (n=6/18) in 1st-AMB+POSnew versus 52.0% (n=26/50) in 1st-AMB; and 0.0% (n=0/22) in SAL-POSnew versus 4.4% (n=2/45) in SAL-POSsusp]. Conclusions: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Citovat

SALMANTON-GARCIA, Jon; Danila SEIDEL; Philipp KOEHLER; Sibylle C. MELLINGHOFF; Raoul HERBRECHT; Nikolai KLIMKO; Zdeněk RÁČIL; Iker FALCES-ROMERO; Paul INGRAM; Angel BENITEZ-PENUELA; Jose RODRIGUEZ; Guillaume DESOUBEAUX; Aleksandra BARAC; Carolina GARCIA-VIDAL; Martin HOENIGL; Sanjay R. MEHTA; Matthew P. CHENG; Galina KLYASOVA; Werner J. HEINZ; Nousheen IQBAL; Robert KRAUSE; Helmut OSTERMANN; Olaf PENACK; Enrico SCHALK; Donald C. SHEPPARD; Birgit WILLINGER; Hilmar WISPLINGHOFF a J. Janne VEHRESCHILD. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy. OXFORD: Oxford University Press, 2019, roč. 74, č. 11, s. 3315-3327. ISSN 0305-7453. Dostupné z: https://doi.org/10.1093/jac/dkz344.

@article{1607046,
   author = {SalmantonandGarcia, Jon and Seidel, Danila and Koehler, Philipp and Mellinghoff, Sibylle C. and Herbrecht, Raoul and Klimko, Nikolai and Ráčil, Zdeněk and FalcesandRomero, Iker and Ingram, Paul and BenitezandPenuela, Angel and Rodriguez, Jose and Desoubeaux, Guillaume and Barac, Aleksandra and GarciaandVidal, Carolina and Hoenigl, Martin and Mehta, Sanjay R. and Cheng, Matthew P. and Klyasova, Galina and Heinz, Werner J. and Iqbal, Nousheen and Krause, Robert and Ostermann, Helmut and Penack, Olaf and Schalk, Enrico and Sheppard, Donald C. and Willinger, Birgit and Wisplinghoff, Hilmar and Vehreschild, J. Janne},
   article_location = {OXFORD},
   article_number = {11},
   doi = {https://doi.org/10.1093/jac/dkz344},
   keywords = {LIPOSOMAL AMPHOTERICIN-B; MYCOSES STUDY-GROUP; TRANSPLANT RECIPIENTS; EUROPEAN-ORGANIZATION; TABLET FORMULATION; FUNGAL-INFECTIONS; ORAL TABLET; PHARMACOKINETICS; THERAPY; SAFETY},
   language = {eng},
   issn = {0305-7453},
   journal = {Journal of Antimicrobial Chemotherapy},
   title = {Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)},
   url = {http://dx.doi.org/10.1093/jac/dkz344},
   volume = {74},
   year = {2019}
}

TY  - JOUR
ID  - 1607046
AU  - Salmanton-Garcia, Jon - Seidel, Danila - Koehler, Philipp - Mellinghoff, Sibylle C. - Herbrecht, Raoul - Klimko, Nikolai - Ráčil, Zdeněk - Falces-Romero, Iker - Ingram, Paul - Benitez-Penuela, Angel - Rodriguez, Jose - Desoubeaux, Guillaume - Barac, Aleksandra - Garcia-Vidal, Carolina - Hoenigl, Martin - Mehta, Sanjay R. - Cheng, Matthew P. - Klyasova, Galina - Heinz, Werner J. - Iqbal, Nousheen - Krause, Robert - Ostermann, Helmut - Penack, Olaf - Schalk, Enrico - Sheppard, Donald C. - Willinger, Birgit - Wisplinghoff, Hilmar - Vehreschild, J. Janne
PY  - 2019
TI  - Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)
JF  - Journal of Antimicrobial Chemotherapy
VL  - 74
IS  - 11
SP  - 3315-3327
EP  - 3315-3327
PB  - Oxford University Press
SN  - 03057453
KW  - LIPOSOMAL AMPHOTERICIN-B
KW  - MYCOSES STUDY-GROUP
KW  - TRANSPLANT RECIPIENTS
KW  - EUROPEAN-ORGANIZATION
KW  - TABLET FORMULATION
KW  - FUNGAL-INFECTIONS
KW  - ORAL TABLET
KW  - PHARMACOKINETICS
KW  - THERAPY
KW  - SAFETY
UR  - http://dx.doi.org/10.1093/jac/dkz344
L2  - http://dx.doi.org/10.1093/jac/dkz344
N2  - Background: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods: We performed a case-matched analysis with proven or probable IM patients from the FungiScope (R) Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n=4/5) of patients receiving 1st-POSnew, for 27.8% (n=5/18) receiving 1st-AMB+POSnew and for 50.0% (n=11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n=1/5) in 1st-POSnew versus 53.3% (n=8/15) in 1st-AMB; 33.3% (n=6/18) in 1st-AMB+POSnew versus 52.0% (n=26/50) in 1st-AMB; and 0.0% (n=0/22) in SAL-POSnew versus 4.4% (n=2/45) in SAL-POSsusp]. Conclusions: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.
ER  -

SALMANTON-GARCIA, Jon; Danila SEIDEL; Philipp KOEHLER; Sibylle C. MELLINGHOFF; Raoul HERBRECHT; Nikolai KLIMKO; Zdeněk RÁČIL; Iker FALCES-ROMERO; Paul INGRAM; Angel BENITEZ-PENUELA; Jose RODRIGUEZ; Guillaume DESOUBEAUX; Aleksandra BARAC; Carolina GARCIA-VIDAL; Martin HOENIGL; Sanjay R. MEHTA; Matthew P. CHENG; Galina KLYASOVA; Werner J. HEINZ; Nousheen IQBAL; Robert KRAUSE; Helmut OSTERMANN; Olaf PENACK; Enrico SCHALK; Donald C. SHEPPARD; Birgit WILLINGER; Hilmar WISPLINGHOFF a J. Janne VEHRESCHILD. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). \textit{Journal of Antimicrobial Chemotherapy}. OXFORD: Oxford University Press, 2019, roč.~74, č.~11, s.~3315-3327. ISSN~0305-7453. Dostupné z: https://doi.org/10.1093/jac/dkz344.

Přehled o publikaci